NCT00763555

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

A Multicenter, Randomized, Vehicle-controlled, Efficacy and Safety Study of CD2027 3µg/g Oily Spray Applied Twice Daily for 8 Weeks in Subjects With Plaque-type Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	CD 2027	Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
DRUG	Calcitriol Vehicle	Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-01-01
• Completion: 2009-03-01
• First posted: 2008-10-01
• Last updated: 2022-08-23
• Results posted: 2022-08-23

Locations

6 sites across 2 countries: United States, Canada